CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — Shareholder Meeting (June 2018)

21 slides from CASI Pharmaceuticals's shareholder meeting presentation, Jun 11, 2018

  1. Slide 1: Corporate Presentation 2018 Annual Stockholder's Meeting

    Corporate(Presentation 2018(Annual(Stockholder’s(Meeting June(11,(2018 Rockville,(Maryland

  2. Slide 2: Forward-Looking Statements

    Forward'Looking-Statements This presentation contains forward'looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward' looking statemen

  3. Slide 3: Investment Highlights (1)

    Investment-Highlights-(1) • Management:(Experienced-team-with-accomplished-track-record-in-North-America-and- China • Diversified product portfolio: ― In#licensed*FDA*approved*products*for*greater*China*from*Spectrum* Pharmaceuticals ― EVOMELA®-(CE'Melphalan),-granted-priority-review-by-China-Food-a

  4. Slide 4: Investment Highlights (2)

    Investment-Highlights-(2) • Compelling(business(model:(Capitalizing-on-critical-U.S./China-synergies-&-competitive- advantages-for-efficient/cost'effective-drug-development-and-commercialization ― Rockville,-MD ― Corporate-office,-senior-management,-finance,-accounting,-compliance,- regulatory-opera

  5. Slide 5: Business Premise

    Business-Premise • 1.4-billion-people-in-China-+-325-million-people-in-the-U.S.-demand-high-quality-and- affordable-medicines • Recent-CFDA-reforms-allow-for-expedited-approvals-of-FDA-ANDAs-and-innovative- products • CASI-is-in-a-unique-position-to-leverage-the-CFDA-reforms-by-introducing-FDA'appro

  6. Slide 6: Financial Highlights

    Financial-Highlights 12(Months(Ended(December(31, Three(Months(Ended(March(31 2017 2016 2018 2017 Total(revenues $ ' $ ' $ ' $ ' Research(&(development 7,595,182 4,645,560 1,697,232 1,049,287 General(&(administrative 3,156,138 4,775,050 1,303,122 644,163 Net(loss (10,770,202) (9,453,488) (3,590,910)

  7. Slide 7: Bi-Cultural Board & Management Team

    Bi'Cultural-Board-&-Management-Team BOARD(OF(DIRECTORS Dr.(WeiGWu(He, Executive(Chairman( IDG'ACCEL-China-Fund-Venture-Partner;-Managing-Director-of- ETP-Global-Fund,-L.P.;-Chairman-&-CEO,-OriGene Technologies,-Inc. Dr.(Quan Zhou Founder,-Managing-Director-and-General-Partner-at-IDG- Capital- Partne

  8. Slide 8: Diversified Product Portfolio

    Diversified-Product-Portfolio- Through*Acquisitions,*In#licensing*and*Internally*Developed*Innovative,* Targeted*Oncology*Therapeutics*and*High*Quality*ANDAs Greater(China(Rights Acquired)From)SPPI US(FDA(ANDAs ENMDG2076,(Global(Rights Acquired)From)Sandoz •25-FDA-Approved-ANDAs Innovative-Drug-Cand

  9. Slide 9: Licensed Products

    Licensed-Products • CASI-entered-into-licensing-agreement-with-Spectrum-Pharmaceuticals-for-China-development- &-commercialization-of-three-hematological-oncology-products • Exclusive(rights(to(three(commercial(products: ― EVOMELA ® Conditioning)treatment)prior)to)autologous)stem)cell)transplant)for

  10. Slide 10: Evomela: China Market Potential

    Evomela®:-China-Market-Potential-- • Status:-CFDA*priority*review;*Expert*Clinical*Advisory*Committee*meeting*took*place*on* April*26,*2018 • Import-drug-application-for-EVOMELA-granted-priority(review(by-CFDA,-underpinning-high- unmet-medical-need-and-advantages-to-currently-available-therapeutics

  11. Slide 11: Marqibo: China Market Potential

    Marqibo®:-China-Market-Potential-- • Status:(CFDA*review*in*progress • Proprietary-liposomal-formulation-of-vincristine-which-improves-pharmacokinetics- and-pharmacodynamics-of-vincristine* – Higher)maximum)tolerated)dose,)superior)antitumor)activity)and)higher) amounts)of)active)drug)delivered)to)t

  12. Slide 12: Zevalin: China Market Potential

    Zevalin®:-China-Market-Potential-- • Status:*CFDA*review*in*progress • Anti'CD20-antibody-coupled-to-Yttrium'90 ̶ 83%-ORR,-39%-CR-in-relapsed-or-refractory,-low'grade-or-follicular-B'cell- NHL (FNHL) • Annual-incidence-of-NHL-in-China-estimated-at-~84k-new-cases-with-mortality-of- ~50k-cases-in-2015

  13. Slide 13: 29 ANDA Products & Pipeline

    29-ANDA-Products-&-Pipeline 25(FDA(Approved,(4(Pending(FDA(Approval(ANDAs Diverse.Portfolio.Across.Attractive. Therapeutic.Area 12% 35% 19% 15% 8% 11% Hypertension/PVD Metabolic.Disorders CNS AntiFinfectious AntiFinflammatory/pain Others Slide-13

  14. Slide 14: Historical Opportunity for FDA-Approved ANDAs in China

    Historical-Opportunity-for-FDA'Approved-ANDAs-in-China Rapidly)Establishing)Leading)Position)in)China’s)>$100B)Small)Molecule)Drug)Market) Rapid(Entry( Technology(Barriers,( Opportunity(for( Industry(Consolidations CFDA’s(BioG CFDA’s(BE( Waiver(on( FDA(ANDA( Equivalence( Products ReGEvaluation( Chin

  15. Slide 15: China Market for 5 Key ANDA Products

    China-Market-for-5-Key-ANDA-Products- Key(Products(Based(on(2016((Estimated)(Generic(Sales(in(China Product Indication 2016E(Sales((in(US$) 1 Entecavir(tablet Chronic(HBV(Infection 1,490,000,000 2 Bisoprolol-Fumarate- Hypertension 205,000,000 tablet 3 Desvenlafaxine SR-tablet Depression 170,000,000

  16. Slide 16: U.S. Market for 8 Key ANDA Products

    U.S.-Market-for-8-Key-ANDA-Products Key(ANDAs(2016(U.S.(Sales* Product(Name Indications Sandoz(U.S.(Sales( Overall(U..S(Generic( 2016((IMS(data) Sales(2016((IMS(data) 1 Midodrine Hypotension 19,800,000 56,900,000 2 Triamterene-/-HCTZ-cap- Hypertension,-diuretic 4,600,000 54,000,000 3 Lisinopril-tab

  17. Slide 17: ENMD-2076 Update (1)

    ENMD'2076-Update-(1) • Clear)Cell)Ovarian)Carcinoma)(CCOC) – Phase-2-data-presented-at-the-2017-Annual-Meeting-of-the-American-Society-of-Clinical- Oncology.-1/38-patients-responded,-several-patients-with-protracted-stable-disease – Biomarker)studies)ongoing • Soft)Tissue)Sarcoma)(STS). – Phase-2-da

  18. Slide 18: ENMD-2076 Update (2)

    ENMD'2076-Update-(2) • Fibrolamellar)Carcinoma)(FLC). The-accrual-to-this-ongoing-Phase-2-study-is-complete- and-is-in-data-clean-up-and-analysis-phase.-It-is-anticipated-that-the-data-from-this- study-will-be-submitted-to-a-medical-conference-for-presentation-in-2018.--- • Phase-1/2-study-in-patien

  19. Slide 19: Summary

    Summary • On track with a Diversified product portfolio: ― In#licensed*FDA*approved*products*for*greater*China*from*Spectrum* Pharmaceuticals ― EVOMELA®-(CE'Melphalan),-granted-priority-review-by-China-Food-and-Drug- Administration-(CFDA)- ― MARQIBO®-(vinCRIStine-sulfate-LIPOSOME),-CFDA-review-in-pr

  20. Slide 20: Thank you

    Thank you harmaceuticals

  21. Slide 21: NASDAQ: CASI www.casipharmaceuticals.com

    NASDAQ:-CASI www.casipharmaceuticals.com

CASI Pharmaceuticals — Shareholder Meeting (June 2018) on 6ix